Baird Initiates Coverage On Soleno Therapeutics with Outperform Rating, Announces Price Target of $72
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney initiates coverage on Soleno Therapeutics (NASDAQ:SLNO) with an Outperform rating and a price target of $72.
May 10, 2024 | 9:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird initiated coverage on Soleno Therapeutics with an Outperform rating and a price target of $72, indicating a positive outlook on the stock.
Analyst ratings, especially from reputable firms like Baird, can significantly influence investor perception and stock prices. An Outperform rating coupled with a high price target suggests Baird's strong belief in Soleno Therapeutics' future performance, potentially leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100